The national law firm of Parker Waichman LLP has filed two lawsuits in Superior Court of New Jersey, Law Division, Atlantic County, against Merck Sharp & Dohme Corp., Watson Pharmaceuticals, Inc., and Teva Pharmaceuticals USA, Inc., on behalf of two women who say they suffered femur fractures because of their long term use of Fosamax (Alendronate).
Pennsylvania plaintiff Irene Zarra began using Fosamax in February 2004 and suffered a left femur fracture in February 2010. Connecticut plaintiff Lucille Handle used Fosamax from January 2006 to February 2010 when she suffered a right femur fracture. Handle suffered a left femur fracture in November of that year also.
According to both lawsuits, the plaintiffs suffered physical and mental pain and suffering, and will continue to sustain permanent injury and emotional distress because of their injuries. The plaintiffs also claim they will continue to suffer economic losses due to medical expenses and living related expenses because of their new lifestyles.
Both lawsuits claim the plaintiffs would never have used Fosamax had they known of the risks associated with the long-term use of Fosamax. “These women are just two examples of the hundreds of women that have suffered unnecessary femur fractures because they used a product that has no proven long-term efficacy,” states Matthew McCauley, who is the leading attorney in the Bisphosphonate Litigation Group at Parker Waichman LLP investigating Fosamax, Actonel and Boniva related femur fracture. “We look forward to the start of the first trials in this litigation, tentatively scheduled for the fall.”
The lawsuits seek compensatory, punitive, and treble damages, reimbursement for the cost of Fosamax, as well as reimbursement for the past, present, and future health and medical costs related to their injuries. The lawsuits also seeks derivative damages.